<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Excessive stimulation of <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> (<z:chebi fb="0" ids="31882">NMDA</z:chebi>) receptors during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> contributes to apoptotic and excitotoxic nerve cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="18344">Kynurenic acid</z:chebi> is a selective <z:chebi fb="68" ids="48706">antagonist</z:chebi> at the glycine co-<z:chebi fb="4" ids="48705">agonist</z:chebi> site of the <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptor complex at low concentration, and it is a broad-spectrum excitatory amino acid receptor blocker at high concentration </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="18344">Kynurenic acid</z:chebi> provides neuroprotection in animal models of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> only at very high doses as it hardly crosses the blood-brain barrier </plain></SENT>
<SENT sid="3" pm="."><plain>The neuroprotective effect of <z:chebi fb="0" ids="16946">L-kynurenine</z:chebi> <z:chebi fb="0" ids="16189">sulfate</z:chebi>, a precursor of <z:chebi fb="0" ids="18344">kynurenic acid</z:chebi>, was therefore studied because <z:chebi fb="0" ids="16946">L-kynurenine</z:chebi> readily crosses the blood-brain barrier </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="16946">L-kynurenine</z:chebi> <z:chebi fb="0" ids="16189">sulfate</z:chebi> was administered 15 min before permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> produced by electrocoagulation of the distal middle cerebral artery in mice </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="16946">L-kynurenine</z:chebi> <z:chebi fb="0" ids="16189">sulfate</z:chebi> induced a small decrease in the surface area of the <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> (10%, P&lt;0.05) at 30 mg/kg i.p., and it caused strong reductions in <z:mpath ids='MPATH_124'>infarct</z:mpath> size (24-25%, P&lt;0.01) at 100 and 300 mg/kg i.p </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment of gerbils with <z:chebi fb="0" ids="16946">L-kynurenine</z:chebi> <z:chebi fb="0" ids="16189">sulfate</z:chebi> at 300 mg/kg i.p </plain></SENT>
<SENT sid="7" pm="."><plain>2 h before a 3-min bilateral carotid occlusion decreased (40%, P&lt;0.01) the pyramidal cell loss in the CA1 area of the hippocampus </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, <z:chebi fb="0" ids="16946">L-kynurenine</z:chebi> <z:chebi fb="0" ids="16189">sulfate</z:chebi> inhibited the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced hypermotility (77%, P&lt;0.001), and decreased (50%, P&lt;0.01) the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced deterioration of spontaneous alternation, a measure of spatial memory, without altering the rectal temperature </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, the administration of <z:chebi fb="0" ids="16946">L-kynurenine</z:chebi> can elevate the brain concentration of <z:chebi fb="0" ids="18344">kynurenic acid</z:chebi> to neuroprotective levels, suggesting the potential clinical usefulness of <z:chebi fb="0" ids="16946">L-kynurenine</z:chebi> for the prevention of <z:hpo ids='HP_0002529'>neuronal loss</z:hpo> </plain></SENT>
</text></document>